• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    3/8/24 12:31:06 PM ET
    $AIMD
    $AMLX
    $CASI
    $EFTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email

    Gainers

    • Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 137.8% to $3.02 during Friday's regular session. The market value of their outstanding shares is at $40.4 million.
    • Ainos (NASDAQ:AIMD) stock moved upwards by 91.96% to $2.15. The company's market cap stands at $10.0 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) shares increased by 34.75% to $1.28. The company's market cap stands at $18.9 million.
    • Joint (NASDAQ:JYNT) stock rose 29.1% to $11.8. The market value of their outstanding shares is at $174.1 million. The company's, Q4 earnings came out yesterday.
    • Lantern Pharma (NASDAQ:LTRN) stock rose 25.11% to $8.32. The market value of their outstanding shares is at $89.3 million.
    • Grifols (NASDAQ:GRFS) stock increased by 19.69% to $6.71. The market value of their outstanding shares is at $4.5 billion.

    Losers

    • Amylyx Pharma (NASDAQ:AMLX) shares declined by 81.5% to $3.52 during Friday's regular session. The market value of their outstanding shares is at $238.2 million.
    • Immuron (NASDAQ:IMRN) stock fell 25.94% to $3.37. The market value of their outstanding shares is at $19.1 million.
    • Jin Medical International (NASDAQ:ZJYL) shares fell 22.94% to $7.09. The company's market cap stands at $1.1 billion.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) shares fell 16.55% to $12.51. The market value of their outstanding shares is at $42.7 million.
    • CASI Pharmaceuticals (NASDAQ:CASI) stock declined by 14.27% to $4.84. The market value of their outstanding shares is at $64.4 million.
    • Turnstone Biologics (NASDAQ:TSBX) stock declined by 13.72% to $3.46. The market value of their outstanding shares is at $79.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $AMLX
    $CASI
    $EFTR

    CompanyDatePrice TargetRatingAnalyst
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    Amylyx Pharmaceuticals Inc.
    $AMLX
    7/10/2025$10.00Buy
    Goldman
    Amylyx Pharmaceuticals Inc.
    $AMLX
    6/24/2025$17.00Buy
    Guggenheim
    Amylyx Pharmaceuticals Inc.
    $AMLX
    6/17/2025$12.00Buy
    Citigroup
    Amylyx Pharmaceuticals Inc.
    $AMLX
    5/30/2025Buy
    TD Cowen
    Amylyx Pharmaceuticals Inc.
    $AMLX
    4/7/2025$7.00Neutral → Outperform
    Mizuho
    Grifols S.A.
    $GRFS
    2/12/2025Overweight
    Morgan Stanley
    Turnstone Biologics Corp.
    $TSBX
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $AIMD
    $AMLX
    $CASI
    $EFTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Jobson Charles E bought $130,874 worth of Common (15,397 units at $8.50), increasing direct ownership by 0.94% to 1,645,294 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/17/26 5:36:26 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Large owner Jobson Charles E bought $3,898 worth of Common (448 units at $8.70), increasing direct ownership by 0.03% to 1,639,597 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/13/26 5:16:01 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Large owner Jobson Charles E bought $174,780 worth of Common (17,478 units at $10.00), increasing direct ownership by 1% to 1,639,149 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    1/27/26 8:45:38 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    $AIMD
    $AMLX
    $CASI
    $EFTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 2, 2022 - FDA Roundup: September 2, 2022

    For Immediate Release: September 02, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:   On Thursday, the FDA published the FDA Voices: “Using A Whole-Of-Governments Approach to Combating Illicit Health Products,” by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office. Crimi

    9/2/22 1:46:13 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMLX
    $CASI
    $EFTR
    SEC Filings

    View All

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    3/5/26 8:03:36 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Amylyx Pharmaceuticals Inc.

    S-8 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    3/3/26 4:03:34 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    3/3/26 4:01:24 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMLX
    $CASI
    $EFTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Amylyx Pharmaceuticals with a new price target

    Stifel initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    3/3/26 8:26:33 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Amylyx Pharmaceuticals with a new price target

    Goldman resumed coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    7/10/25 8:47:27 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Amylyx Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $17.00

    6/24/25 7:57:48 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMLX
    $CASI
    $EFTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Frates James M was granted 95,990 shares, increasing direct ownership by 58% to 261,628 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/9/26 4:00:07 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Mazzariello Gina was granted 74,660 shares, increasing direct ownership by 56% to 209,090 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/9/26 4:00:08 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Cohen Joshua B was granted 248,865 shares, increasing direct ownership by 7% to 3,583,548 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/9/26 4:00:10 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMLX
    $CASI
    $EFTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

    MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time). A copy of the presentation slide deck is available on the Company's website: https://investors.immuron.com.au/announcements/7418301 COMPANY CONTACT: Steven LydeamoreChief Executive [email protected] About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing

    3/5/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

    NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the successful export of fully GMP-compliant manufactured psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. The product was manufactured at the Psyence Labs Ltd. ("PsyLabs") GMP-controlled production facility, supporting pharmaceutical-grade psychedelic development. The shipment represents an operational achievement for both Psyence BioMed and PsyLabs, reinforcing their shared commitment to establishing a regulated global supply

    3/3/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMLX
    $CASI
    $EFTR
    Financials

    Live finance-specific insights

    View All

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Joint Corp. to Report 2025 Fourth Quarter and Full Year Results on Thursday, March 12 and Host Conference Call and Webcast

    SCOTTSDALE, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT) the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its 2025 fourth quarter and full year financial results on Thursday, March 12, 2026, after the market close and host a conference call and simultaneous webcast at 5:00 p.m. ET that day. During the call, The Joint Corp. President and CEO Sanjiv Razdan and CFO Scott Bowman will review the Company's financial results and provide a business update, followed by a question-and-answer session. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing

    2/26/26 7:05:00 AM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Amylyx's senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.c

    2/24/26 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMLX
    $CASI
    $EFTR
    Leadership Updates

    Live Leadership Updates

    View All

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

    NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard ph

    1/5/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMLX
    $CASI
    $EFTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care